AMPK promotes macrophage fatty acid oxidative metabolism to mitigate inflammation: Implications for diabetes and cardiovascular disease

Immunology and Cell Biology

Volumn 92, Issue 4, 2014, Pages 340-345

  Steinberg, Gregory R ^a   Schertzer, Jonathan D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENYLATE KINASE; ADIPONECTIN; CRYOPYRIN; CYTOKINE; INFLAMMASOME; INSULIN; LEPTIN; METFORMIN; SALICYLIC ACID; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

AEROBIC METABOLISM; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; FATTY ACID METABOLISM; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MACROPHAGE; METABOLIC REGULATION; METABOLIC STRESS; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE PHOSPHORYLATION; REVIEW; ANIMAL; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FATTY ACIDS; HUMANS; INFLAMMATION; MACROPHAGES; OXIDATION-REDUCTION;

EID: 84899446511     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2014.11     Document Type: Review

References (88)

1. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N et al. Diabetes mell itus, fasting glucose, and risk of cause-specific death. New Engl J Med 2011; 364: 829-841.
2. Woollard KJ. Immunological aspects of atherosclerosis. Clin Sci 2013; 125: 221-235.
3. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
4. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nature reviews. Immunology 2008; 8: 923-934.
5. Winer S, Winer DA. The adaptive immune system as a fundamental regulator of adipose tissue inflammation and insulin resistance. Immunol Cell Biol 2012; 90: 755-762.
6. Lumeng CN, Maillard I, Saltiel AR. T-ing up inflammation in fat. Nat Med 2009; 15: 846-847.
7. Lumeng CN. Innate immune activation in obesity. Mol Aspect Med 2013; 34: 12-29.
8. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010; 316: 129-139.
9. Bhargava P, Lee CH. Role and function of macrophages in the metabolic syndrome. Biochem J 2012; 442: 253-262.
10. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 2013; 339: 161-166.
11. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L et al. Macrophage-speci fic PPAR[ggr] controls alternative activation and improves insulin resistance. Nature 2007; 447: 1116-1120.
12. Olefsky JM Glass CK. Macrophages Inflammation and Insulin Resistance Annu Rev Physiol 2010 72 219-246.
13. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004 110: 1564-1571.
14. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
15. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003 112: 91-100.
16. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin I nvest 1996; 97: 1715-1722.
17. Hunninghake DB, Stein EA, Dujovne CA, Harris WS, Feldman EB, Miller VT et al. The efficacy of intensive dietary therapy alone or combined with lovastatin in o utpatients with hypercholesterolemia. New Engl J Med 1993; 328: 1213-1219.
18. Cho KY, Miyoshi H, Kuroda S, Yasuda H, Kamiyama K, Nakagawara J et al. The phenotype of infiltrating macr ophages influences arteriosclerotic plaque vulnerability in the carotid artery. J Stroke Cerebrovasc Dis 2013; 22: 910-918.
19. Steinberg GR. Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance. Cell Cycle 2007; 6: 888-894.
20. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010; 140: 900-917.
21. Zhou J, Werstuck GH, Lhotak S, de Koning AB, Sood SK, Hossain GS et al. Association of multiple cellular stress pathways with accelerated atherosclerosis in hyperhomocysteinemic apolipoprotei n E-deficient mice. Circulation 2004; 110: 207-213.
22. Zhou J, Lhotak S, Hilditch BA, Austin RC. Activation of the unfolded protein response occurs at all stages of atherosclerotic lesion develop ment in apolipoprotein E-deficient mice. Circulation 2005; 111: 1814-1821.
23. Austin RC, Lentz SR, Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 2004; 11(Suppl 1), S56-S64.
24. Dickhout JG, Hossain GS, Pozza LM, Zhou J, Lhotak S, Austin RC. Peroxynitrite causes endoplasmic reticulum stress and apoptosis in human vascular endothelium: implications in atherogenesis. Arterioscler Thromb Vasc Biol 2005; 2 5: 2623-2629.
25. Feng B, Yao PM, Li Y, Devlin CM, Zhang D, Harding HP et al. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol 2003; 5: 781-792.
26. Myoishi M, Hao H, Minamino T, Watanabe K, Nishihira K, Hatakeyama K et al. Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrom e. Circulation 2007; 116: 1226-1233.
27. Hung JH, Su IJ, Lei HY, Wang HC, Lin WC, Chang WT et al. Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through act ivation of NF-kappaB and pp38 mitogen-activated protein kinase. J Biol Chem 2004; 279: 46384-46392.
28. Urano F, Wang X, Bertolotti A, Zhang Y, Chung P, Harding HP et al. Coupling of s tress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 2000; 287: 664-666.
29. O'Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 2009; 61: 177-197.
30. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008; 226: 10-18.
31. Flamment M, Hajduch E, FerréP, Foufelle F. New insights into ER stress-induced insulin resistance. Trends Endocrinol Metab 2012; 23: 381-390.
32. Tannahill GM, O'Neill LA. The emerging role of metabolic regulation in the functioning of Toll-like receptors and the NOD-like receptor Nlrp3. FEBS Lett 2011; 585: 1568-1572.
33. Wen H, Ting JP, O'Neill LA. A role for the NLRP3 inflammasome in metabolic diseases-did Warburg miss inflammation Nat Immunol 2012; 13: 352-357.
34. Haneklaus M O'Neill LA Coll RC Modulatory mechanisms con trolling the NLRP3 inflammasome in inflammation: recent developments Curr Opin Immunol 2013 25 40-45.
35. Shao W, Yeretssian G, Doiron K, Hussain SN, Saleh M. The Caspase-1 digestome ident ifies the glycolysis pathway as a target during infection and septic shock. J Biol Chem 2007; 282: 36321-36329.
36. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger Science 2010; 327: 296-300.
37. Lerner Alana G, Upton J-P, Praveen PVK, Ghosh R, Nakagawa Y, Igbaria A et al. IRE1a induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremedia ble er stress. Cell Metab 2012; 16: 250-264.
38. Oslowski Christine M, Hara T, O'Sullivan-Murphy B, Kanekura K, Lu S, Hara M et al. Thioredoxin-interacting protein mediates ER stress-induced b cell death through initiation of the inflammasome. Cell Metab 2012; 16: 265-273.
39. Lee H-M, Kim J-J, Kim HJ, Shong M, Ku BJ, Jo E-K. Upregulated NLRP3 inflammasome activation in patients with Type 2 diabetes. Diabetes 2013; 62: 194-204.
40. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG et al. NLRP3 inflammasomes are required for ather ogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-1361.
41. Vandanmagsar B, Youm Y-H, Ravussin A, Galgani JE, Stadler K, Mynatt RL et al. The NLRP3 inflammasome i nstigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17: 179-188.
42. Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT-H et al. Fatty acid-induced NLRP3-ASC infl ammasome activation interferes with insulin signaling. Nat Immunol 2011; 12: 408-415.
43. Lawlor KE, Vince JE. Ambiguities in NLRP3 inflammasome regulation: Is there a role for mitochondria Biochim Biophys Acta 2014; 1840: 1433-1440.
44. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011; 469: 221-225.
45. Wascher TC LJ, Sourij H, Kooistra T, Pacini G, Roden M. Chronic TNF-a neutralization does not improve insulin resistance or endothelial function in"healthy" men with metabolic syndrome. Mol Med 2011; 17: 189-193.
46. Mart́nez-Abundis E, Reynoso-von Drateln C, Hernández-Salazar E, González-Ortiz M. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res 2007; 299: 461-465.
47. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev 2009; 89: 1025-1078.
48. Hardie DG, Ross FA, Hawley SA. AMP-activated protein kinase: a target for drugs both ancient and modern. Chem Biol 2012; 19: 1222-1236.
49. O'Neill HM, Holloway GP, Steinberg GR. AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: implications for obesity. Mol Cell Endocrinol 2013; 366: 135-151.
50. Galic S, Fullerton MD, Schertzer JD, Sikkema S, Marcinko K, Walkley CR et al. Hematopoietic AMPK b1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J Clin Investig 2011; 121: 4903-4915.
51. Fullerton MD, Steinberg GR, Schertzer JD. Immunometabolism of AMPK in insulin resistance and atherosclerosis. Mol Cell Endocrinol 2013; 366: 224-234.
52. Carroll KC, Viollet B, Suttles J. AMPKa1 deficiency amplifies proinflammatory myeloid APC activity and CD40 signaling. J Leukocyte Biol 2013; 94: 1113-1121.
53. Sag D, Carling D, Stout RD, Suttles J. Adenosin e 50-monophosphate- activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol 2008; 181: 8633-8641.
54. Steinberg GR, Michell BJ, van Denderen BJW, Watt MJ, Carey AL, Fam BC et al. Tumor necrosis factor a-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab 2006; 4: 465-474.
55. Yang Z Kahn BB Shi H Xue B-z Macrophage a1 AMP-activated protein kinase (a1AMPK) antagonizes fatty acid-induced inflammation through SIRT1 J Biol Chem 2010 285 19051-19059.
56. Tavakoli S, Zamora D, Ullevig S, Asmis R. Bioenergetic profiles diverge during macrophage polarization: implications for the interpretation of 18 F-FDG PET imaging of atherosclerosis. J Nuclear Med 2013; 54: 1661-1667.
57. Rodŕguez-Prados J-C, Través PG, Cuenca J, Rico D, Aragonés J, Mart́n-Sanz P et al. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J Immunol 2010; 185: 605-614.
58. Steinberg GR, Dandapani M, Hardie DG. AMPK: mediating the metabolic effects of salicylate-based drugs Trends Endocrinol Metab 2013; 24: 481-487.
59. McGettrick AF, O'Neill LA. How metabolism generates signals during innate immunity and inflammation. J Biol Chem 2013; 288: 22893-22898.
60. Pearce EL, Poffenberger MC, Chang C-H, Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. Science 2013; 342: 6155.
61. O'Neill LAJ, Hardie DG. Metabolism of inflammation limited by AMPK and pseudostarvation. Nature 2013; 493: 346-355.
62. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 2011; 27: 441-464.
63. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 2013; 496: 238-242.
64. Gauthier MS, O'Brien EL, Bigornia S, Mott M, Cacicedo JM, Xu XJ et al. Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans. Biochem Biophys Res Commun 2011; 404: 382-387.
65. Mounier R, Théret M, Arnold L, Cuvellier S, Bultot L, Göransson O et al. AMPKa1 regul ates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration. Cell Metab 2013; 18: 251-264.
66. Cacicedo JM, Yagihashi N, Keaney JF Jr., Ruderman NB, Ido Y . AMPK inhibits fatty acid-induced increases in NF-kB transactivation in cultured human umbilical vein endothelial cells. Biochem Biophys Res Commun 2004; 324: 1204-1209.
67. Giri S, Nath N, Smith B, Viollet B, Singh AK, Singh I. 5-Aminoimidazole-4-Carboxamide-1-b-4-Ribofuranoside inhibits proinflammatory response in glial cells: a possible role of amp-activated protein kinase. J Neurosci 2004; 24: 479-487.
68. Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci 1991; 88: 2441-2445.
69. Yang Z, Wang X, He Y, Qi L, Yu L, Xue B et al. The full capacity of AICAR to reduce obesity-induced inflammation and insulin resistance requires myeloid SIRT1. PLoS One 2012; 7: e49935.
70. Jeong HW, Hsu KC, Lee J-W, Ham M, Huh JY, Shin HJ et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol-Endocrinol Metabol 2009; 296: E955-E964.
71. Ji G, Zhang Y, Yang Q, Cheng S, Hao J, Zhao X et al. Genistein suppresses LPS-induced inflammatory response through inhibiting NF-kB following AMP kinase activation in RAW 264.7 macrop hages. PLoS One 2012; 7: e53101.
72. Dong J, Zhang X, Zhang L, Bian H-X, Xu N, Bao B et al. Quercetin reduces obesityassociated adipose tissue macrophage infiltration and inflammation in mice: a mechanism including AMPKa1/SIRT1. J Lipid Res 2014; 55: 363-374.
73. Zong Y, Sun L, Liu B, Deng Y-S, Zhan D, Chen Y-L et al. Resveratrol inhibits LPSinduced MAPKs activati on via activation of the phosphatidylinositol 3-kinase pathway in murine RAW 264.7 macrophage cells. PLoS One 2012; 7: e44107.
74. Xue B, Yang Z, Wang X, Shi H. Omega-3 polyunsaturated fatty acids antagonize macrophage inflammation via activation of AMPK/SIRT1 pathway. PLoS One 2012; 7: e45990.
75. Neumeier M Weigert J Schäffler A Wehrwein G Müller-Ladner U Schölmerich J et al. Different effects of adiponectin isoforms in human monocytic cells J Leukocyte Biol 2006 79 803-808.
76. Pinkosky SL, Filippov S, Srivastava RAK, Hanselman JC, Bradshaw CD, Hurley TR et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res 2013; 54: 134-151.
77. Filippov S, Pinkosky SL, Lister RJ, Pawloski C, Hanselman JC, Cramer CT et al. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J L ipid Res 2013; 54: 2095-2108.
78. Galic S, Fullerton MD, Schertzer JD, Sikkema S, Marcinko K, Walkley CR et al. Hematopoietic AMPK beta1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J Clin Inves t 2011; 121: 4903-4915.
79. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012; 336: 918-922.
80. Bianchi A, Evans JL, Iverson AJ, Nordlund AC, Watts TD, Witters LA. Identification of an isozymic form of acetyl-CoA carboxylase. J Biol Chem 1990; 265: 1502-1509.
81. Fullerton MD, Galic S, Marcinko K, Sikkema S, Chen ZP, Schertzer JD et al. A single phosphorylation-site in ACC1 and 2 is essential for regulating liver lipid homeostasis and t he beneficial effects of metformin. Nat Med 2013; 19: 1649-1654.
82. Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W et al. Phosphorylation of ULK1 (hATG1) by AMP-ac tivated protein kinase connects energy sensing to mitophagy. Science 2011; 331: 456-461.
83. O'Neill HM, Maarbjerg SJ, Crane JD, Jeppesen J, Jorgensen SB, Schertzer JD et al. AMP-activated protein kinase (AMPK) beta1beta2 muscle null mice reveal an essential role for AMPK in maintaining mitochondrial content and glucose uptake during exercise. Proc Natl Acad Sci USA 2011; 108: 16092-16097.
84. Harris J, Hartman M, Roche C, Zeng SG, O'Shea A, Sharp FA et al. Autophagy controls IL-1b secretion by targe ting Pro-IL-1b for degradation. J Biol Chem 2011; 286: 9587-9597.
85. Bachar-Wikstrom E, Wikstrom JD, Kaiser N, Cerasi E, Leibowitz G. Improvement of ER stress-induced diabetes by stimulating autophagy. Autophagy 2013; 9: 626-628.
86. Bachar-Wikstrom E, Wikstrom JD, Ariav Y, Tirosh B, Kaiser N, Cerasi E et al. Stimulation of autophagy improves endoplasmic reticulum stress-induced diabetes. Diabetes 2013; 62: 1227-1237.
87. Maiuri MC, Grassia G, Platt AM, Carnuccio R, Ialenti A, Maffia P. Macrophage autophagy in atherosclerosis. Mediat Inflamm 2013; 2013: 14.
88. Mei S, Gu H, Ward A, Yang X, Guo H, He K et al. p38 Mitogen-activated protein kinase (MAPK) promotes cholesterol ester accumulation in macrophages through inhibition of macroa utophagy. J Biol Chem 2012; 287: 11761-11768.